Compare Charles River Laboratories Intl. Inc (CRL) vs iShares MSCI Australia ETF (EWA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs iShares MSCI Australia ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $227.69 (market cap $11.14B), while iShares MSCI Australia ETF trades at $28.75. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, iShares MSCI Australia ETF nearer its low. Which is the better fit depends on your goals.
| CRL | EWA | |
|---|---|---|
Market Cap | $11.14B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $233.60 | $30.26 |
52-Week Low | $145.57 | $24.95 |
Enterprise Value | $14.00B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
EWA trades at $28.35, down 0.35% with a bullish technical signal from moving averages. The stock shows neutral oscillator readings with RSI at 57.64. Recent dividend announcement of $0.40 payable June 2026 provides income potential. Support levels cluster around $28 with resistance at $29.
Outlook remains cautiously optimistic given technical strength, though limited fundamental data availability warrants careful evaluation. Key catalysts include dividend payments and broader market trends. Risks include market volatility and Australia-specific economic factors affecting performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →
